(Q24241707)

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Anakinra treatment of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Interleukin-1 receptor antagonist treatment of rheumatoid arthritis patients: radiologic progression and correlation of Genant/Sharp and Larsen scoring methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Efficacy of anakinra in bone: comparison to other biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Erosion healing in rheumatoid arthritis after anakinra treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Guidelines for the management of rheumatoid arthritis: 2002 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Infliximab for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Etanercept for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

A proposed revision to the ACR20: The hybrid measure of American College of Rheumatology response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Measurement of patient outcome in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Controlling the risk of spurious findings from meta-regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Adalimumab for treating rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

From the Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treat

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

IX 207-887 in rheumatoid arthritis. A double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

The many worlds of reducing interleukin-1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

[Kineret, Enbrel, Remicade and company. Recombinant drugs in rheumatoid arthritis]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

[Treatment of chronic polyarthritis with a human recombinant interleukin 1 receptor antagonist]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

The trials of anakinra

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

[Treatment of rheumatoid arthritis with anakinra: a systematic review]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: radiologic assessment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

Bone destruction in arthritis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005121.PUB3

7 January 2021

10.1002/14651858.CD005121.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

release_o7i5xidwq5by5bxrdvssvc7p7i

1894714

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/o7i5xidwq5by5bxrdvssvc7p7i

24 November 2022

mapped directly with Wikidata item

1894714

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference